Professor John Bridgewater

After qualifying in medicine and surgery in 1986, Professor Bridgewater specialised in medical oncology at the Middlesex, Mount Vernon and Royal Marsden Hospitals.  He undertook a PhD in gene therapy at the Institute of Cancer Research, and subsequently took a senior lecturer position in medical oncology at UCL in 1999.

Professor Bridgewater led the National Cancer Research Institute (NCRI) subgroup in hepatobiliary malignancy, focussing on clinical and translational research.  He has contributed to landmark studies in gastrointestinal (GI) malignancy and is chief and co-chief investigator on a number of lead studies in the NCRI upper-GI research portfolio.  He is senior author on the BILCAP and ABC-02 studies that have defined the management of biliary tract cancer in the adjuvant and advanced settings respectively.  He was a lead investigator on the New EPOC study and has helped develop the portfolios of the colorectal and pancreatic subgroups.

Professor Bridgewater serves on several research committees including the Clinical Trials Advisory and Awards Committee, and the National Institute for Health and Care Excellence committee.  He also leads the clinical service for CUP in the Integrated London Cancer Consortium.